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 IMMUNOSUPPRESSED PATIENTS 
The immune system is a highly complex physiological cascade that protects 
the body from ‘foreign’ pathogens. A defect at any point in this system can 
lead to both an increase in the incidence and an increase in the severity of 
infections. An immunosuppressed patient is unable to mount the normal, co-
ordinated immune response to trauma and infection. The aetiology of the 
immune defects can be divided into primary (congenital) or secondary 
(acquired) disorders. 
 
Figure 1 
 
Improvements in the treatment of immune disorders have increased the 
number of referrals and admissions to the ICU. Patients may present because 
of their primary illness or a new pathology which is complicated by their 
immunosuppressant therapy, for example a perforated viscus.  
 
Whilst chronic illnesses such as diabetes mellitus can predispose to a degree 
of immunosuppression, the groups that will be discussed in this chapter 
include: 
• Patients with cancer or haematological malignancies. 
• Recipients of solid organ transplants. 
• Patients with HIV/AIDS. 
• Patients with asplenia or functional hyposplenism. 
GENERAL CONSIDERATIONS 
Infection 
Respiratory failure or sepsis are the commonest reasons for 
immunosuppressed patients to require ICU admission. The exceptions to this 
are patients post solid organ transplant.  
Whilst there is no specific therapy for the immunosuppressed patient, the 
principles outlined in the surviving sepsis guideline (www.survivingsepsis.org) 
should be followed.  
Immunosuppressed patients may be critically ill yet display little in the way of 
signs or symptoms. This key point means a detailed history, together with a 
high index of clinical suspicion is vital. Knowing the aetiology of the 
immunosuppression can provide invaluable clues as to the likely pathogen 
causing the infection. For example, neutropenia confers susceptibility to 
bacteraemia whilst long-term steroids (>15-20mg/day) increase host 
susceptibility to viruses, fungi and parasites as well as bacteria.  
The infections they sustain are often of greater severity and may have a rapid 
progression. The prior use of prophylactic and therapeutic antibiotics may 
mean that the potential for resistant organisms is increased. Microbiological 
diagnosis should be pursued and early liaison with microbiology is vital to 
ensure broad spectrum cover. Invasive procedures such as CT guided needle 
biopsy, broncho-alveolar lavage and transbronchial biopsy may be required to 
obtain a sample of sputum or tissue when a respiratory source is suspected. 
These investigations can lead to further complications, especially if patients 
are requiring high inspired concentrations of oxygen and high PEEP levels. 
When infection is suspected, a reduction in the dose of immunosuppressant 
therapy may be equally as important as commencing antibiotics to allow an 
adequate host response.  
Particular risk factors for developing infection include: 
• Neutropenia. An absolute neutrophil count below 0.5x109/L or those in 
whom the neutrophil count is falling rapidly. 
• New leukaemia or lymphoma. 
• Recent haematopoietic stem cell transplant (HSCT) recipients and 
allogenic HSCT recipients with significant degrees of graft versus host 
disease (GvsHD). 
• Recent infections especially due to cytomegalovirus (CMV), or with 
known colonisation with fungi or resistant bacteria.  
• Co morbid illnesses requiring hospitalisation. 
• The use of peripheral and central venous catheters and urinary 
catheters. 
 
Respiratory failure 
Respiratory failure can result from multiple simultaneous pulmonary 
processes, both infectious and non infectious. Non infectious complications 
include thromboembolism, tumour, radiation pneumonitis, atelectasis, 
pulmonary oedema, drug allergy or toxicity and pulmonary haemorrhage. 
In addition to the usual ‘common’ pathogens, these patients are at increased 
risk of opportunistic infections and reactivation of latent infections such as 
toxoplasmosis, herpes viral infections or tuberculosis.  
The common pathogens include: 
Bacteria:  Streptococcus pneumoniae, 
Haemophilus Influenzae 
Mycoplasma 
Legionella 
Viruses:  CMV is the most common virus of concern, especially in 
transplant recipients and is often difficult to distinguish from non 
invasive viral infection. Its incidence is related to the intensity of 
the immunosuppressant therapy and usually occurs in the first 
few months post transplant. In patients not receiving prophylaxis 
pneumocystis jiroveci/carinii (PCP) is associated with CMV 
infection. 
Fungi:  Cryptococcus neoformans  
Aspergillus. Invasive aspergillosis is increasing in incidence and 
is associated with a high mortality. 
Pneumocystis jiroveci/carinii is not uncommon in patients 
receiving steroids as part of a chemotherapeutic or maintenance 
regimen. 
 
SPECIAL CONSIDERATIONS 
Patients with cancer and haematological malignancies 
As a consequence of both the primary illness and its treatment, patients with 
malignancies are prone to episodes of neutropenia. The presence of a fever 
in a neutropenic patient is to be taken seriously. It is often the only sign of a 
bacteraemia. Factors contributing to the pathogenesis of infection include the 
direct effects of chemotherapy on mucosal barriers and the immune deficits 
related to the underlying malignancy. 
The likelihood of there being an underlying bacterial cause is greatest when 
the neutrophil count is < 1x109/L. The high mortality associated with gram 
negative organisms has led to the use of prophylactic antibiotics; however 
gram positive organisms are now common isolates, especially in patients with 
long term vascular access catheters. Validated regimens that are commonly 
used include antipseudomonal penicillin and aminoglycoside or a single agent 
regimen such as a third generation cephalosporin or a penem. As these 
agents give relatively poor gram positive cover consideration should be given 
to introducing vancomycin.  
After 5 days, if the patient has continued fever but is clinically stable and has 
resolving neutropenia, the initial antibiotic regimen can be continued.  
However, if there is evidence of progressive disease then consideration 
should be given to changing or adding further antibiotics. Treatment should 
continue for at least 1 week and ideally until the neutrophil count is > 
0.5x109/L or 14 days have elapsed.  
 A high, swinging pyrexia in the absence of a readily identifiable focus should 
raise the possibility of a deep fungal infection. Fungi are common pathogens 
and the risk of a fungaemia increases with the duration and severity of 
neutropenia, prolonged antibiotic use and the number of chemotherapy 
cycles. Consideration should be given to adding an antifungal agent if there is 
a persistent temperature after 72 hours. 
 
Unique considerations post haematopoietic stem cell transplant (HSCT) 
HSTC can be either autologous (derived from the patient) or allogenic (from a 
donor). Despite advances, the success of HSCT remains limited by severe 
complications that are related to the toxicity of the conditioning regimen 
required prior to allogenic HSCT, immunosuppression and GvsHD disease. 
Complications usually occur in the first 100 days post HSCT. The presence of 
more than 1 organ failure, regardless of organ type increases the mortality in 
this patient population. Mortality rates of 75-85% have been quoted in patients 
requiring mechanical ventilation.  
HSCT recipients are prone to unique pulmonary complications.  
? Engraftment syndrome.  Occurs within 96 hours of engraftment and 
can arise in autologous and allogenic recipients. It can cause fever, 
erythematous rash, diarrhoea, renal impairment and multiorgan failure. 
The syndrome coincides with neutrophil recovery and the treatment is 
supportive. 
? Diffuse alveolar haemorrhage.  Injury to the endothelial cells of small 
blood vessels and thrombotic microangiopathy due to high dose 
chemotherapy can cause this condition. Symptoms include progressive 
dyspnoea, cough, fever and hypoxia. The treatment is supportive, 
however the prognosis is poor with most patients dying of sepsis and 
multiorgan failure rather than respiratory failure. 
? Idiopathic pneumonia syndrome is a syndrome of diffuse lung injury 
that develops post HSCT where an infectious cause is not found. 
? Bronchiolitis Obliterans Organising Pneumonia (BOOP) is related to 
GvsHD and usually responds to steroids. It has a good prognosis and 
doesn’t usually require critical care services. 
 Infection and complications in solid organ transplant recipients 
Despite rigorous screening, transmission of infection from the donor organ 
can occur. Some donors may have active infection at the time of procurement. 
Fever, bacteraemia or even mycotic aneurysms at anastomotic sites can 
occur in the recipients. Proof of adequate treatment of such infections must be 
established prior to organ donation. Other infections may not be apparent, or 
be accelerated in the recipient, after commencing immunosuppressant 
therapy.  
Viral infections, especially CMV and Epstein-Barr virus (EBV), can cause 
particular problems in the transplant recipient. The greatest risk is seen in the 
seronegative recipient and seropositive donor. 
Late, latent infections, including TB, can also activate many years after 
transplantation. 
Not surprisingly, lung transplant patients have a higher risk of developing 
pulmonary infection than other solid organ transplant recipients. Reasons for 
this include: 
? An extended intubation period leading to colonisation of the lower 
respiratory tract.  
? Trauma sustained by the lung during transplantation. 
? Mechanical factors such as decreased ciliary action and reduced 
cough reflex. 
Complications post organ transplant can be divided into 3 timelines:- 
Up to 6 weeks post transplant: 
Infections can be derived from the donor or recipient; in addition there is the 
potential for the usual post-operative infectious complications and hospital 
acquired infections. In these patients the effects of immunosuppression are 
not often evident unless they have been receiving immunosuppressant 
therapy pre-operatively.  
1-6 months post transplant: 
It is in this time period that patients are at most risk of developing 
opportunistic infections, although problems from the perioperative period can 
persist. The major infections due to opportunistic pathogens include PCP, 
latent infections, viral pathogens and TB. Viruses can also cause direct 
clinical effects such as fever and neutropenia (CMV), pneumonitis (respiratory 
viruses), hepatitis (HBV, HCV) etc.  
Graft rejection is thought to be mediated by proinflammatory cytokine release 
and may require an increase in immunosuppressant therapy leading to an 
increased risk of opportunistic infection.  
After 6 months:  
At this time most patients are receiving stable and reduced levels of 
immunosuppression and are prone to the usual community acquired 
pathogens. 
Common Immunosuppressant Drugs 
? Steroids limit cytokine and chemokine synthesis, induce apoptosis and 
limit acquired immune responses predominantly by attenuating T cell 
actions. The risk of infection is dose and time related. The highest risk 
occurs with doses >0.5 mg/kg/day of prednisolone or equivalent 
agents, or a cumulative total dose of >700mg. The risk of sepsis is 
related to diminished phagocytosis and killing of bacterial and fungal 
pathogens. Long term therapy can cause defects in cell mediated 
immunity and cause opportunistic infections. 
? Cytoreductive agents induce dose related reductions in rapidly 
dividing cell lines and causing neutropenia and mucositis. When used 
in lower doses as an immune modulator, methotrexate has been 
associated with opportunistic infections. 
? Immunophilin binding agents are used primarily in transplantation, 
limiting cytotoxic T-lymphocyte expansion and graft rejection. This is 
achieved by attenuating the signalling system for IL-2 production by 
calcineurin inhibition (cyclosporine and tacrolimus) or inhibition of 
lymphocyte mRNA transplantation and IL-2 synthesis (sirolimus or 
rapamycin). As they primarily affect T cells the risk of bacterial and 
fungal infection is quite low. 
? Mycophenolate specifically inhibits the de novo pathway of purine 
synthesis in B and T cells. There is specific inhibition of lymphocyte 
clonal expansion on exposure to appropriate antigens. The risk of 
sepsis is reduced but its use has been associated with opportunistic, 
intracellular viral infections, specifically CMV disease and EBV 
associated with lymphoproliferative disorder. 
? Anti-TNF agents inhibit the host innate and acquired immune 
responses to microbial pathogens. Anti-TNF treatment (infliximab, 
etanercept) is used in severe RA and Crohn’s and has been associated 
with severe, disseminated infection.  
 
HIV AND AIDS 
With the advent of highly active antiretroviral therapy (HAART), the prognosis 
of patients with HIV and AIDS has improved enormously. Compared with 
other ICU groups with similar severity of illness, HIV patients no longer have a 
worse outcome.  Patients are increasingly admitted to the ICU with HIV as a 
co morbid disease rather than as the primary admission reason.  
HIV and its therapy can cause multisystem problems:  
Respiratory failure still remains the commonest cause for ICU admission. 
This can be due to varied pathologies including, PCP, TB or other 
mycobacterial disease. Patients with PCP and a pneumothorax requiring 
mechanical ventilation still have a mortality approaching 100%. 
Cardiac disease can occur in these patients as HAART is associated with 
atherogenesis and metabolic complications such insulin resistance and 
diabetes. It is also known that HIV patients who undergo percutaneous 
coronary intervention have higher restenosis rates than those who do not. 
End stage liver disease secondary to viral hepatitis can cause significant 
morbidity and mortality. Patients receiving concurrent HIV and HBV treatment 
should ideally continue both therapies as severe relapses of hepatitis B may 
occur if it is stopped. 
Renal impairment is a frequent cause of mortality and morbidity. Treatment 
options include renal replacement therapy +/- transplantation. The HIV 
infection itself appears to be the cause of HIV associated nephropathy and in 
this clinical scenario HAART can slow disease progression. 
Immunologic reconstitution can occur when established HAART therapy 
reduces the viral load and causes a general increase in pro-inflammatory 
mediators and effects. A number of disorders are related to this and are 
collectively termed the immune reconstitution inflammatory syndrome (IRIS). 
With the addition of steroids HAART can often be continued in this situation. 
Co-infection of HIV and HCV has major mortality effects. HCV related deaths 
are more common after improved HIV treatment with HAART. It appears that 
impaired cellular immunity from HIV leads to accelerated HCV reproduction. 
Conversely HCV has also accelerated the progression of HIV disease. 
Antiretroviral therapy in ICU 
HAART generally consists of 2 nucleoside reverse transcriptase inhibitors 
(NRTI’s) and either 1 non-nucleoside reverse transcriptase inhibitor (NNRTI) 
or 1or 2 protease inhibitors (PI’s). 
Table 1  
General principles for deciding on whether to commence HAART in the ICU 
are as follows. 
? If the patient is not on treatment but admitted with an AIDS related 
illness, consider commencing antiretrovirals. 
?  If not admitted with an AIDS related illness this decision can probably 
be deferred. If the CD4 count is less than 200/mm3 and the patient is 
having a prolonged ICU stay consider treatment, as this increases risk 
of an opportunistic infection. 
The main problems encountered with HAART in the ICU are: 
? CONTINUATION OF DRUG THERAPY  
Achieving adequate plasma levels in those patients that cannot 
swallow may be problematic. If an oral solution is not available, tablets 
or capsules have to be crushed. If the enteral route cannot be utilised, 
few drugs have an intravenous formulation. Potential problems, 
therefore include sub therapeutic drug levels and drug resistance, or 
supra therapeutic drug levels and adverse effects. In addition, 
discontinuing HAART in the ICU is undesirable, as it may also lead to 
the selection of a drug resistant virus. 
? PHARMACOKINETICS AND PHARMACODYNAMICS 
Commonly used ICU interventions such as enteral feeding, proton 
pump and H2 antagonists can affect the pharmacokinetics and 
pharmacodynamics of antiretrovirals.  
Renal insufficiency decreases the clearance of most nucleoside 
reverse transcriptase inhibitors (NRTI’s) therefore these patients 
cannot use most of the fixed dose NRTI combinations. Hepatic 
impairment will also decrease the metabolism of many protease 
inhibitors and NNRTI’s.  
? DRUG INTERACTIONS 
There are many interactions between antiretrovirals and common ICU 
drugs; protease inhibitors are particularly vulnerable as they are 
metabolised by the cytochrome P450 system. Commonly used drugs 
that can interact with HAART include: 
Midazolam: Interacts with most PI’s and NNTRI’s leading to 
increased sedative effects. 
Amiodarone, Dlitiazem and Nifedipine: Interact with some PI’s to 
cause increased cardiac effects. 
? TOXICITY 
HAART has decreased the incidence of AIDS related illnesses 
however it has been implicated in rare life threatening conditions such 
as Stevens Johnston syndrome. Other toxic side-effects include 
pancreatitis, lipodystrophy, insulin resistance and hyperlipidaemia. 
NNRTI’s can cause a fatal lactic acidosis by disrupting mitochondrial 
DNA replication by selective inhibition of DNA polymerase-γ. This can 
cause hepatic steatosis, lactic acidosis or mitochondrial myopathy. 
Treatment involves stopping the drug. 
 
ASPLENIA 
Splenic macrophages have an important filtering and phagocytic role in 
removing bacteria and parasitized red cells from the circulation. Life 
threatening infection is a major long term risk post splenectomy. Most serious 
infections are due to encapsulated bacteria.  
With the advent of vaccinations, this risk can be minimised and national 
guidelines are in place to offer prophylaxis to all patients who have either 
undergone a surgical splenectomy or have functional hyposplenism (sickle 
cell, thalassaemia major, lymphoproliferative disorders, bone marrow 
transplant). 
Vaccines against pneumococcus, meningococcus and Haemophilus influenza 
B should be administered 2 weeks prior to an elective splenectomy or as soon 
as possible after surgery and certainly prior to hospital discharge. These 
patients are also offered the flu vaccine on a yearly basis. 
 Lifelong antibiotics should be offered to all patients, however, the first 2 years 
post splenectomy appears especially important. The antibiotic prophylaxis of 
choice is oral phenoxymethylpenicillin 250-500mg twice daily or erythromycin 
if the patient is penicillin allergic.  
Keypoints 
? Immunosuppressed patients may be critically unwell, yet display minimal 
clinical signs and symptoms. 
? In addition to the usual pathogenic organisms, these patients are prone 
to opportunistic infections and reactivation of latent infections. Knowing 
the aetiology of the immunosuppression can help target therapy.  
? Early liaison with microbiologists is vital to ensure patients are given 
appropriate broad spectrum cover. 
? Patients with HIV and those post HSCT can have their own unique 
clinical syndromes. 
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TABLE 1 
 
Nucleoside reverse 
transcriptase inhibitor 
Protease inhibitor:  Non-nucleoside reverse 
transcriptase inhibitor 
Zidovudine Amprenavir Efavirenz 
Abacavir Fosamprenavir Nevirapine 
Didanosine Indinavir  
Emitricitabine Lopinavir  
Lamivudine Nelfinavir  
Stavudine Ritonavir  
Tenofovir Saquinavir  
Zalcitabin   
 
 
